Disputes Between South Korean Local Drug Makers And Multinationals Increasing, Expected To Get Worse
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Patent disputes between South Korean pharmaceutical companies and multinational companies are on the rise as locals try to produce generics of products approaching their patent expiration dates, according to a government report
You may also be interested in...
South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers
SEOUL - South Korean pharmaceutical companies are bracing for a tough time ahead if the governments of South Korea and the U.S. ratify a long-awaited Free Trade Agreement hammered out last year after eight rounds of negotiations between the two countries
Sanofi-Aventis Loses Patent Lawsuit In Korea Over Oxaliplatin
SHANGHAI - Sanofi-Aventis lost a patent lawsuit in South Korea, after the country's Supreme Court dismissed its appeal to nullify patents obtained by Korea-based Boryung Pharmaceutical for its generic drug for colorectal cancer, Boryung announced Oct. 20
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).